Relevance of chemotherapy dose and schedule to outcomes in ovarian cancer
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Reference30 articles.
1. Cancer statistics, 2004;Jemal;CA Cancer J Clin,2004
2. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer;Muggia;J Clin Oncol,2000
3. Surgical advances in the treatment of ovarian cancer;Li;Hematol Oncol Clin North Am,2003
4. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer;Ozols;J Clin Oncol,2003
5. Clinical trials of newer regimens for treating ovarian cancer;Copeland;Gynecol Oncol,2003
Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Tratamiento del cáncer de cuello uterino en estadio III y IV;EMC - Ginecología-Obstetricia;2023-02
2. Polymeric Nanoparticle Delivery of Combination Therapy with Synergistic Effects in Ovarian Cancer;Nanomaterials;2021-04-20
3. Dose-dense chemotherapy: A possible high cost-effectiveness treatment for ovarian cancer;Taiwanese Journal of Obstetrics and Gynecology;2020-05
4. Comparing Paclitaxel–Carboplatin with Paclitaxel–Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer;International Journal of Environmental Research and Public Health;2020-03-26
5. MUL1 E3 ligase regulates the antitumor effects of metformin in chemoresistant ovarian cancer cells via AKT degradation;International Journal of Oncology;2019-02-27
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3